<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940952</url>
  </required_header>
  <id_info>
    <org_study_id>2012-03-065</org_study_id>
    <secondary_id>2012-03-065</secondary_id>
    <nct_id>NCT01940952</nct_id>
  </id_info>
  <brief_title>Zydena on Cognitive Function of Alzheimer's Disease Patients</brief_title>
  <official_title>Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Zydena (Udenafil) has positive effect on
      cognitive function in patients with Alzheimer's disease.

      This study is a randomized, double blind, placebo-controlled multicenter study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>from baseline to Week 12 and Week 24 after the administration of the medication</time_frame>
    <description>measured by ADAS-cog</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>from baseline to Week 12 and Week 24</time_frame>
    <description>Measured by MMSE, Clinical Dementia Rating Sum of Boxes, ADCS-ADL, COWAT, Digit Symbol Coding, Trail Making Test-E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in behavioral symptoms</measure>
    <time_frame>from baseline to Week 12 and Week 24</time_frame>
    <description>Measured by Neuropsychiatric Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain function</measure>
    <time_frame>from baseline to Week 12 and Week 24</time_frame>
    <description>Measured by FDG-PET</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Zydena 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Donepezil 5mg or 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zydena 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg</intervention_name>
    <arm_group_label>Zydena 50mg</arm_group_label>
    <other_name>Zydena 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Donepezil 5mg or 10mg</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg</intervention_name>
    <arm_group_label>Zydena 100mg</arm_group_label>
    <other_name>Zydena 100mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent;

          -  Male or female subjects 50 to 90 years of age;

          -  Diagnosis of probable Alzheimer's disease according to National Institute of
             Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders
             Association (NINCDS/ADRDA) criteria;

          -  A Mini-Mental State Examination (MMSE) score of ≥10 and ≤26;

          -  Global Clinical Dementia Rating ≥ 0.5;

          -  Mild to moderate (not severe) white matter hyperintensities on brain MRI performed
             within three years from screening;

          -  Good enough hearing and visual function to complete neuropsychological tests

          -  Caregivers living with patients or spending 10 or more hours a week with patients;

          -  Stable dose of donepezil (5mg to 10mg) for at least 60 days;

          -  If patients have been on memantine, it should be washed out for at least 60 days;

          -  Medications including anxiolytics, antipsychotics, and hypnotics may be taken if the
             dose has been stable for at least two weeks

        Exclusion Criteria:

          -  History of stroke within 6 months;

          -  Previous diagnosis of severe (more than 80%) intracranial artery stenosis;

          -  History of heart failure, ischemic heart disease (myocardial infarction, unstable
             angina, and stable angina), hypertrophic cardiomyopathy, and life-threatening
             arrhythmia;

          -  Previous history of coronary artery bypass graft surgery;

          -  Severe symptom of orthostatic hypotension (orthostatic syncope or presyncope),
             especially when patients take alpha-adrenergic blocker (Alfuzosin, Doxazosin,
             Naftopidil, Tamsulosin, Terazosin, Arotinolol, Carvedilol, Labetalol, Trazodone,
             typical and atypical antipsychotics);

          -  Uncontrolled diabetes mellitus;

          -  Proliferative diabetic retinopathy;

          -  Severe hypotension (blood pressure less than 90/50mmHg) or severe hypertension (blood
             pressure more than 170/100mmHg);

          -  Hepatic dysfunction (AST or ALT more than three times of upper normal limit) or renal
             dysfunction (serum creatinine more than 2.5mg/dL);

          -  Retinitis pigmentosa;

          -  Previous history of active peptic ulceration within one year before screening;

          -  Hematodyscrasia susceptible to priapism including sickle cell anemia, multiple
             myeloma, leukemia, and various bleeding disorders;

          -  History of drug abuse;

          -  Medication including nitrates/nitric oxide donor (ex: nitroglycerin, isosorbide
             mononitrate, isosorbide dinitrate, amyl nitrate/nitrite, and Sodium nitroprusside),
             androgen (ex: testosterone), anti-androgen, and anticoagulants;

          -  Current cancer chemotherapy;

          -  Usage of PDE5i (Zydena, Viagra®, Levitra®, or Cialis®) within two weeks before study
             start;

          -  History of hypersensitive reaction to PDE5i (Zydena, Viagra®, Levitra®, or Cialis®)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enda Go, Clinical Research Coordinator</last_name>
    <phone>82-2-3410-2868</phone>
    <email>ed.ko@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duk L. Na, MD. PhD</last_name>
    <phone>82-2-3410-3599</phone>
    <phone_ext>3599</phone_ext>
    <email>dukna@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samguns Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enda Go, Clinical Research Coordinator</last_name>
      <phone>82-2-3410-2868</phone>
      <email>ed.ko@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Duk L. Na, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Duk Lyul Na</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

